biosimilars

Biosimilar familiarity expandsDermatologists and some psoriasis patients might soon grapple with switching from a biologic to a biosimilar.
Supreme Court Ruling Raises Biosimilars’ AccessHigh court ruling should make biosimilars available faster.
Samsung Gets First U.S. ApprovalThe second Remicade biosimilar is only the fifth biosimilar approved in the United States.
Top challenges likely to slow adoption of biosimilarsBiosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption.
FDA approvals for specialty drugs to pick up in 2017Numerous specialty medications, generics, and biosimilars, are expected to be approved this year for cancer, inflammatory and autoimmune diseases, and other indications.
Understanding and using biosimilarsBiosimilars have the potential to lower the high costs of biologic treatments for patients suffering from chronic skin diseases. Although biosimilars have received FDA approval derms still have many questions about what they are and when they may be used appropriately. Patent wars and a lack of rules and regulations at the state level add to the confusion about using biosimilars.
Will new autoimmune drugs address cost concerns?Find out what’s in the drug pipeline for autoimmune disease.
Are payers optimistic about biosimilars’ savings?As more biosimilars are approved, plans and PBMs will continue to evolve their strategies regarding coverage and formulary management of these new medications.
  • 1
  • 2